Answer
Dabrafenib mesilate should be used during pregnancy only if the potential maternal benefit outweighs the possible fetal risk; human pregnancy data are absent, animal studies show reproductive and developmental toxicity including teratogenicity, and trametinib's prescribing information must also be consulted if used together.
Sources for this answer
- Tafinlar 50 mg & 75 mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 40Document updated
Sources checked